142 related articles for article (PubMed ID: 34387605)
41. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F
Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440
[TBL] [Abstract][Full Text] [Related]
42. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Molenaar JP; Baten A; Blokx WA; Hoogendam A
Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
[TBL] [Abstract][Full Text] [Related]
43. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
44. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
45. Hormone therapy for radiorecurrent prostate cancer.
Payne H; Khan A; Chowdhury S; Davda R
World J Urol; 2013 Dec; 31(6):1333-8. PubMed ID: 22996761
[TBL] [Abstract][Full Text] [Related]
46. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
47. Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chiu PK; Chan SY; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Asian J Androl; 2017; 19(1):98-102. PubMed ID: 26585698
[TBL] [Abstract][Full Text] [Related]
48. A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Nakai Y; Tanaka N; Anai S; Miyake M; Tatsumi Y; Fujimoto K
Horm Cancer; 2015 Aug; 6(4):161-7. PubMed ID: 26024831
[TBL] [Abstract][Full Text] [Related]
49. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
50. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
Cussenot O; Cornu JN; Drouin SJ; Mozer P; Egrot C; Vaessen C; Haab F; Bitker MO; Rouprêt M
World J Urol; 2014 Apr; 32(2):545-50. PubMed ID: 24166289
[TBL] [Abstract][Full Text] [Related]
51. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
[TBL] [Abstract][Full Text] [Related]
52. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
53. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
[TBL] [Abstract][Full Text] [Related]
54. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
McPartlin AJ; Glicksman R; Pintilie M; Tsuji D; Mok G; Bayley A; Chung P; Bristow RG; Gospodarowicz MK; Catton CN; Milosevic M; Warde PR
Cancer; 2016 Aug; 122(16):2595-603. PubMed ID: 27219522
[TBL] [Abstract][Full Text] [Related]
55. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
56. Bicalutamide causes heart failure in an elderly patient with prostate cancer.
Guirguis K
Expert Opin Drug Saf; 2016; 15(3):297-302. PubMed ID: 26745594
[TBL] [Abstract][Full Text] [Related]
57. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
Motofei IG; Rowland DL; Popa F; Kreienkamp D; Paunica S
BJU Int; 2011 Jul; 108(1):110-5. PubMed ID: 20955264
[TBL] [Abstract][Full Text] [Related]
58. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
[TBL] [Abstract][Full Text] [Related]
59. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
60. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
